| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| 8,000 HERCULES CAPITAL INC | 112,142 | 150,560 |
| 750 CBRE GROUP INC CLASS A | 36,454 | 120,593 |
| 250 VANGUARD MEGA CAP GROWTH ETF IV | 47,124 | 103,193 |
| 500 VANGUARD DIVIDEND APPRECIATION ETF | 61,623 | 109,890 |
| 1,800 SPDR S&P BANK ETF | 63,631 | 109,242 |
| 2,000 OMEGA HEALTHCARE INVESTMENTS REIT | 57,318 | 88,680 |
| 1500 ETFMG PRIME CYBER SECURITY ETF | 72,496 | 72,496 |
| 2,000 ENBRIDGE INC | 87,516 | 95,660 |
| 3,000 PROTAGONIST THERAPEUTICS | 74,664 | 262,020 |
| 4,535.23 SH GABELLI GOLD AAA | 125,000 | 211,614 |
| 6,000 SH SPDR SHORT TERM | 181,799 | 181,200 |
| 25,000 SH PYXIS ONCOLOGY INC | 48,912 | 28,750 |
| 800 SH LIGAND PHARMA | 97,808 | 151,256 |
| 5,000 SH INVESCO SENIOR LOAN ETF | 104,525 | 105,000 |
| 2,000 SH GOLDMAN SACHS NASDAQ | 102,260 | 105,740 |
| 5,000 SH AURINIA PHARMACEUTIC | 58,450 | 79,750 |
| 2,000 SH ALTRIA GROUP INC | 112,110 | 115,320 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| 2,000 ISHARES US MEDICAL | AT COST | 61,827 | 124,300 |
| 2,000 SELECT STR FINANCIAL | AT COST | 49,082 | 109,540 |
| 700 SPDR S&P AEROSPACE | AT COST | 58,291 | 168,868 |
| OKAVA BIOPHARMACEUTICALS | AT COST | 125,000 | 125,000 |
| CYRUS BIOTECHNOLOGY | AT COST | 50,000 | 50,000 |
| TAXIS PHARMACEUTICALS | AT COST | 100,000 | 100,000 |
| 2,000 ISHARES SILVER TRUST | AT COST | 42,021 | 128,840 |
| 2,000 DELEK LOGISTICS PARTN LP | AT COST | 66,652 | 89,240 |
| SOLVEIN | AT COST | 50,000 | 50,000 |
| RANDOM ORDER | AT COST | 60,000 | 60,000 |
| QUADRIGA | AT COST | 175,000 | 175,000 |
| NERVANA | AT COST | 50,000 | 50,000 |
| MAXYMUNE | AT COST | 250,000 | 250,000 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| LEGAL FEES | 338 | 0 | 0 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FROM K-1 - INVESTMENT FEES | 108 | 108 | 0 | |
| FROM K-1 1231 GAIN/LOSS | 39 | 39 | 0 | |
| FROM K-1 ORDINARY LOSS | 10,942 | 10,942 | 0 | |
| MISCELLANEOUS EXPENSE | 1,347 | 0 | 0 | |
| NONDEDCUTIBLE EXPENSES | 4 | 0 | 0 |
| Description | Amount |
|---|---|
| PRIOR PERIOD ADJUSTMENT - TO ADJUST NET ASSETS TO ACTUAL | 100,930 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FEDERAL TAXES | 4,494 | 0 | 0 | |
| FOREIGN TAX PAID | 2,170 | 2,170 | 0 |